Abstract
The purpose of this study was to examine whether the introduction of d-Phe could improve the GnRH receptor binding affinities of DOTA-conjugated d-Lys6-GnRH peptides. Building upon the construct of DOTA-Ahx-(d-Lys6-GnRH1) we previously reported, an aromatic amino acid of d-Phe was inserted either between the DOTA and Ahx or between the Ahx and d-Lys6 to generate new DOTA-d-Phe-Ahx-(d-Lys6-GnRH) or DOTA-Ahx-d-Phe-(d-Lys6-GnRH) peptides. Compared to DOTA-Ahx-(d-Lys6-GnRH1) (36.1nM), the introduction of d-Phe improved the GnRH receptor binding affinities of DOTA-d-Phe-Ahx-(d-Lys6-GnRH) (16.3nM) and DOTA-Ahx-d-Phe-(d-Lys6-GnRH) (7.6nM). The tumor targeting and pharmacokinetic properties of 111In-DOTA-Ahx-d-Phe-(d-Lys6-GnRH) was determined in MDA-MB-231 human breast cancer-xenografted nude mice. Compared to 111In-DOTA-Ahx-(d-Lys6-GnRH1), 111In-DOTA-Ahx-d-Phe-(d-Lys6-GnRH) exhibited comparable tumor uptake with faster renal and liver clearance. The MDA-MB-231 human breast cancer-xenografted tumors were clearly visualized by single photon emission computed tomography (SPECT) using 111In-DOTA-Ahx-d-Phe-(d-Lys6-GnRH) as an imaging probe, providing a new insight into the design of new GnRH peptides in the future.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
